Lexicon Pharmaceuticals (NASDAQ:LXRX) Earns Sell Rating from Analysts at StockNews.com

StockNews.com assumed coverage on shares of Lexicon Pharmaceuticals (NASDAQ:LXRX - Free Report) in a report issued on Monday. The brokerage issued a sell rating on the biopharmaceutical company's stock.

Several other equities analysts have also weighed in on LXRX. Needham & Company LLC restated a "hold" rating on shares of Lexicon Pharmaceuticals in a report on Monday, March 3rd. Leerink Partnrs lowered Lexicon Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, March 5th. HC Wainwright reiterated a "buy" rating and set a $4.00 target price on shares of Lexicon Pharmaceuticals in a report on Friday, March 28th. Leerink Partners restated a "market perform" rating and issued a $1.00 target price (down previously from $2.00) on shares of Lexicon Pharmaceuticals in a research note on Tuesday, March 4th. Finally, Piper Sandler cut their price objective on shares of Lexicon Pharmaceuticals from $10.00 to $6.00 and set an "overweight" rating on the stock in a research report on Friday, March 7th. One analyst has rated the stock with a sell rating, three have given a hold rating and two have given a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of "Hold" and an average price target of $3.67.

Lexicon Pharmaceuticals Price Performance

Shares of LXRX stock traded up $0.06 during trading hours on Monday, reaching $0.73. 6,118,568 shares of the company were exchanged, compared to its average volume of 6,411,119. The company has a market cap of $180.49 million, a price-to-earnings ratio of -0.97 and a beta of 1.02. The company has a debt-to-equity ratio of 0.56, a current ratio of 7.45 and a quick ratio of 7.43. The stock's fifty day moving average is $0.49 and its two-hundred day moving average is $0.85. Lexicon Pharmaceuticals has a fifty-two week low of $0.28 and a fifty-two week high of $2.45.

Lexicon Pharmaceuticals (NASDAQ:LXRX - Get Free Report) last posted its quarterly earnings results on Thursday, March 6th. The biopharmaceutical company reported ($0.09) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.11) by $0.02. The business had revenue of $26.55 million for the quarter, compared to analysts' expectations of $6.48 million. Lexicon Pharmaceuticals had a negative return on equity of 107.38% and a negative net margin of 4,109.41%. Sell-side analysts forecast that Lexicon Pharmaceuticals will post -0.66 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Lexicon Pharmaceuticals

A number of large investors have recently added to or reduced their stakes in LXRX. Wellington Management Group LLP increased its holdings in shares of Lexicon Pharmaceuticals by 2.1% in the fourth quarter. Wellington Management Group LLP now owns 747,996 shares of the biopharmaceutical company's stock valued at $552,000 after purchasing an additional 15,249 shares during the last quarter. Arizona State Retirement System boosted its holdings in shares of Lexicon Pharmaceuticals by 34.4% during the 4th quarter. Arizona State Retirement System now owns 62,976 shares of the biopharmaceutical company's stock worth $47,000 after buying an additional 16,136 shares during the period. Teacher Retirement System of Texas raised its holdings in Lexicon Pharmaceuticals by 60.3% in the 4th quarter. Teacher Retirement System of Texas now owns 65,415 shares of the biopharmaceutical company's stock valued at $48,000 after acquiring an additional 24,615 shares during the period. Bank of America Corp DE raised its holdings in Lexicon Pharmaceuticals by 27.4% in the 4th quarter. Bank of America Corp DE now owns 136,407 shares of the biopharmaceutical company's stock valued at $101,000 after acquiring an additional 29,319 shares during the period. Finally, Invesco Ltd. lifted its position in Lexicon Pharmaceuticals by 60.6% during the fourth quarter. Invesco Ltd. now owns 104,494 shares of the biopharmaceutical company's stock worth $77,000 after acquiring an additional 39,420 shares during the last quarter. Institutional investors own 74.70% of the company's stock.

Lexicon Pharmaceuticals Company Profile

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract.